Literature DB >> 25736545

Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.

K A Ponto1,2, T Diana3, H Binder4, N Matheis5, S Pitz6, N Pfeiffer7, G J Kahaly8.   

Abstract

PURPOSE: Recognition of dysthyroid optic neuropathy (DON) requires sensitive diagnostic tools. Clinical assessment may fail to reliably evaluate the acuteness of DON especially if signs for inflammation are missing. Aim of this cross-sectional study was to assess the relationship between thyroid-stimulating immunoglobulins (TSI) and onset of DON.
METHODS: At a multidisciplinary orbital center, serum TSI levels were measured in 180 consecutive patients with thyroid eye disease (TED) and 302 healthy controls with a FDA-cleared cell-based bioassay using a chimeric TSH receptor and a CRE-dependent luciferase.
RESULTS: Thirty of 180 (16.7 %) patients with TED had DON of recent onset or a past history of DON (post-DON). Optic disk swelling was present and visual-evoked potentials were pathologic in all eyes with DON of recent onset, but in one of 13 (7.7 %) with post-DON, only (p = 0.005). 19/20 (96 %) patients with DON of recent onset were TSI-positive. TSI was associated with DON of recent onset (OR: 20.96; 95 % CI 1.064-412.85, p = 0.045). All controls were TSI negative. TSI correlated with the clinical activity score (R = 0.70, p < 0.001) and higher TSI-levels were noted in active vs. inactive TED (485.1 ± 132.3 vs. 277.7 ± 143.7 %, cut-off < 140 %; p < 0.001). Six of seven (85.7 %) patients with inactive TED with recent onset DON versus one of four (25 %) with active post-DON were TSI-positive (p = 0.006). A discriminatory cut-point of 377 SRR % for TSI was determined based on a ROC analysis (sensitivity: 0.95, specificity: 0.8).
CONCLUSIONS: Serum TSI levels identify patients with DON of recent onset requiring urgent therapy.

Entities:  

Keywords:  Dysthyroid optic neuropathy; Thyroid eye disease; Thyroid stimulating immunoglobulins

Mesh:

Substances:

Year:  2015        PMID: 25736545     DOI: 10.1007/s40618-015-0254-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  57 in total

Review 1.  Novel treatment modalities for Graves' orbitopathy.

Authors:  Luigi Bartalena; Adriana Lai; Lorenza Sassi; Valentina Lombardi; Ilaria Dalle Mule; Myriam Gandolfo; Luigi Liparulo; Claudio Azzolini; Eliana Piantanida; Maria Laura Tanda
Journal:  Pediatr Endocrinol Rev       Date:  2010-03

2.  Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity?

Authors:  Colin M Dayan; Margaret R Dayan
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

3.  Quality of life in a german graves orbitopathy population.

Authors:  Katharina A Ponto; Gerhard Hommel; Susanne Pitz; Heike Elflein; Norbert Pfeiffer; George J Kahaly
Journal:  Am J Ophthalmol       Date:  2011-06-14       Impact factor: 5.258

4.  Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients.

Authors:  J Szabó; A Leövey; Z Karányi; C Várvölgyi; E Fórizs; L Herceg
Journal:  Acta Med Hung       Date:  1989

5.  Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.

Authors:  Anja K Eckstein; Marco Plicht; Hildegard Lax; Herbert Hirche; Beate Quadbeck; Klaus Mann; Klaus P Steuhl; Joachim Esser; Nils G Morgenthaler
Journal:  Clin Endocrinol (Oxf)       Date:  2004-11       Impact factor: 3.478

6.  Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins.

Authors:  Johannes J Leschik; Tanja Diana; Paul D Olivo; Jochem König; Ulrike Krahn; Yunsheng Li; Michael Kanitz; George J Kahaly
Journal:  Am J Clin Pathol       Date:  2013-02       Impact factor: 2.493

7.  Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy.

Authors:  J R Guy; S Fagien; J P Donovan; M L Rubin
Journal:  Ophthalmology       Date:  1989-07       Impact factor: 12.079

8.  Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease.

Authors:  V P Michelangeli; C Poon; D J Topliss; P G Colman
Journal:  Thyroid       Date:  1995-06       Impact factor: 6.568

Review 9.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

Review 10.  Diagnostic criteria for Graves' ophthalmopathy.

Authors:  G B Bartley; C A Gorman
Journal:  Am J Ophthalmol       Date:  1995-06       Impact factor: 5.258

View more
  17 in total

Review 1.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

2.  Diagnostic accuracy of Immulite® TSI immunoassay for thyroid-associated orbitopathy in patients with recently diagnosed Graves' hyperthyroidism.

Authors:  Brandon Thia; Myra B McGuinness; Peter R Ebeling; Jwu Jin Khong
Journal:  Int Ophthalmol       Date:  2021-10-06       Impact factor: 2.031

3.  Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.

Authors:  Roshini Fernando; Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

4.  Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies.

Authors:  T Diana; C Wüster; M Kanitz; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2016-05-19       Impact factor: 4.256

5.  Performance and Specificity of 6 Immunoassays for TSH Receptor Antibodies: A Multicenter Study.

Authors:  Tanja Diana; Christian Wüster; Paul D Olivo; Angelica Unterrainer; Jochem König; Michael Kanitz; Artur Bossowski; Brigitte Decallonne; George J Kahaly
Journal:  Eur Thyroid J       Date:  2017-08-08

6.  Prevalence of Radiological Signs of Dysthyroid Optic Neuropathy in Magnetic Resonance Imaging in Patients with Active, Moderate-to-Severe, and Very Severe Graves Orbitopathy.

Authors:  Beata Rutkowska-Hinc; Edyta Maj; Anna Jabłońska; Justyna Milczarek-Banach; Tomasz Bednarczuk; Piotr Miśkiewicz
Journal:  Eur Thyroid J       Date:  2018-02-15

7.  A Novel Long-Term Graves' Disease Animal Model Confirmed by Functional Thyrotropin Receptor Antibodies.

Authors:  Tanja Diana; Hans-Peter Holthoff; Julia Fassbender; Christian Wüster; Michael Kanitz; George J Kahaly; Martin Ungerer
Journal:  Eur Thyroid J       Date:  2020-07-23

8.  Combination Model of Thyrotrophin Receptor Antibody and Volumetric Orbital Apex Crowding Index as an Indicator of Dysthyroid Optic Neuropathy.

Authors:  Zhihong Deng; Lu Chen; Jia Tan; Sha Wang; Dan Liu; Jinwei Wang; Chengzhi Jiang; Jie Yang; Bei Xu
Journal:  Dis Markers       Date:  2021-05-18       Impact factor: 3.434

Review 9.  Thyrotropin Receptor Blocking Antibodies.

Authors:  Tanja Diana; Paul D Olivo; George J Kahaly
Journal:  Horm Metab Res       Date:  2018-10-04       Impact factor: 2.936

10.  2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

Authors:  George J Kahaly; Luigi Bartalena; Lazlo Hegedüs; Laurence Leenhardt; Kris Poppe; Simon H Pearce
Journal:  Eur Thyroid J       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.